Medicare Part B Step Therapy Programs - UHCprovider.com
Non-Preferred Product Step Therapy Criteria Akynzeo, Cinvanti, or Sustol, may be covered when any of the criteria listed below are satisfied: History of use of Aloxi, Emend, Granisetron, or Ondansetron resulting in minimal clinical response to therapy; or
Download Medicare Part B Step Therapy Programs - UHCprovider.com
Information
Domain:
Source:
Link to this page:
Documents from same domain
Coverage Summary - UHCprovider.com Home
www.uhcprovider.comThe benefit information in this Coverage Summary is based on existing national coverage ... Also see the Medicare Prescription Drug Benefit Manual,Chapter 6, ...
UnitedHealthcare Group Medicare Advantage …
www.uhcprovider.comUnitedHealthcare® Group Medicare Advantage (PPO) Plan Network Care Provider Quick Reference Guide Insurance coverage provided by or through UnitedHealthcare Insurance Company or its affiliates.
Shoulder Replacement Surgery (Arthroplasty)
www.uhcprovider.comShoulder Replacement Surgery (Arthroplasty) ... FDA-approved reverse shoulder replacement surgery devices are generally approved for gross rotator cuff deficiency. The patient's joint must be anatomically and structurally suited to receive the selected implant(s), and a functional
NEUROMUSCULAR ELECTRICAL STIMULATION …
www.uhcprovider.comNeuromuscular Electrical Stimulation (NMES) (NCD 160.12) Page 2 of 3 UnitedHealthcare Medicare Advantage Policy Guideline Approved 08/09/2017
APREPITANT FOR CHEMOTHERAPY-INDUCED …
www.uhcprovider.comChemotherapy-induced nausea and vomiting (CINV) can range from mild to severe, with the most severe cases resulting in dehydration, malnutrition, metabolic imbalances, and potential withdrawal from future chemotherapy
Clinical Performance Guideline Medical Fertility Solutions ...
www.uhcprovider.comClinical Performance Guideline Fertility Solutions Infertility Medical Necessity Guideline Purpose: To provide an understanding of infertility treatment, issues surrounding infertility surgery, and issues surrounding multiple embryo transfers among individuals faced with the potential loss of fertility.
EXTRACORPOREAL SHOCK WAVE TREATMENT (ESWT)
www.uhcprovider.comExtracorporeal Shock Wave Treatment (ESWT) Page 1 of 4 ... Extracorporeal shock wave therapy (ESWT), using either a high- or low-dose protocol or a radial wave, is considered not medically necessary for all indications, including but not limited to the treatment of:
Pervasive Developmental Disorder and Autism Spectrum …
www.uhcprovider.comPervasive Developmental Disorder and Autism Spectrum Disorder: Benefit Interpretation Policy (Effective 01/01/2018) 3 Proprietary Information of UnitedHealthcare.
Pervasive Developmental Disorder and Autism Spectrum …
www.uhcprovider.compervasive developmental disorders include autism, Rett's disorder, childhood disintegrative disorder, Asperger's disorder, and unspecified pervasive developmental disorder. E. …
Approval Date: October 10, 2018 - UHCprovider.com Home
www.uhcprovider.comRetinal Prosthesis Page 1 of 3 UnitedHealthcare Medicare Advantage Policy Guideline Approved 10/10/2018 Proprietary Information of UnitedHealthcare.
Related documents
Procedures, programs, and drugs that require precertification
member.aetna.comAvsola (infliximab-axxq) — precertification for the drug and sit e of care required Inflectra (infliximab-dyyb) — precertification for the drug and sit e of care required ... Granix (injection tbo-filgrastim) Leukine (injection sargramostim, GM-CSF) Neulasta (injection pegfilgrastim)
Medical Drug and Step Therapy Prior Authorization List for ...
www.bcbsm.comMedical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue SM and BCN AdvantageSM members Revised March 2022 1 . This document lists the medical benefit drugs that have authorization or step therapy requirements for Medicare Advantage members .
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu14 weeks (i.e. after 4 doses), no additional treatment with infliximab should be given. Re-administration for Crohn’s disease and rheumatoid arthritis . If the signs and symptoms of disease recur, infliximab can be re-administered within 16 weeks following the last infusion. In clinical studies, delayed hypersensitivity reactions have been ...
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) …
www.janssenlabels.com(infliximab) for injection, for intravenous use Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment.
To mix or not to mix – compatibilities of parenteral drug ...
www.nps.org.auHowever, a small number of injection solutions are formulated in non-aqueous solvents to allow dissolution of a poorly water soluble substance in a small volume. In these formulations, dilution of the non-aqueous injection vehicle with water or saline may precipitate the drug. The problem is frequently observed when diazepam injection is diluted.
Provider Administered Drugs – Site of Care – Commercial ...
www.uhcprovider.comInjection, infliximab-axxq, biosimilar, (avsola), 10 mg . Benefit Considerations . This guideline applies to members who have medical necessity language in their Certificate of Coverage (COC) or Summary Plan Document with benefits available for health care services if medically necessary and have been approved for the